{
  "report_rows": [
    {
      "kpi": "Normalized FFO per diluted share",
      "prediction": "BEAT",
      "answer": "pred ~$1.59 vs. cons $1.55",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "SHO same-store NOI growth",
      "prediction": "BEAT",
      "answer": "pred ~21.0% vs. cons 19.5%",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Total revenue",
      "prediction": "BEAT",
      "answer": "pred ~$3.49B vs. cons $3.37B",
      "confidence": "MEDIUM"
    }
  ],
  "guide_rows": [
    {
      "kpi": "FY2026 normalized FFO per diluted share",
      "prediction": "BETTER",
      "answer": "guide ~$6.39 midpoint vs. cons $6.34 (FY2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "FY2026 SHO same-store NOI growth",
      "prediction": "BETTER",
      "answer": "guide ~20.0% midpoint vs. cons 19.5% (FY2026)",
      "confidence": "MEDIUM"
    }
  ],
  "day1_residual_pct": 3.5,
  "day1_confidence": "MEDIUM",
  "day5_residual_pct": 5,
  "day5_path": "FOLLOW-THROUGH",
  "day5_rationale": "A ~2.6% normalized-FFO beat plus a ~5-cent FY2026 midpoint raise would lift second-half and out-year FFO estimates; continued 20% SHO-NOI growth and a full-quarter Amica contribution support upward revisions rather than a one-day valuation-only move.",
  "day5_confidence": "MEDIUM"
}